Page last updated: 2024-11-03

ono 1078 and Atrophy

ono 1078 has been researched along with Atrophy in 1 studies

pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist

Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.

Research Excerpts

ExcerptRelevanceReference
"Oral montelukast (0."1.37Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. ( Fang, SH; Shi, WZ; Wei, EQ; Zhang, YM; Zhao, R, 2011)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhao, R1
Shi, WZ1
Zhang, YM1
Fang, SH1
Wei, EQ1

Other Studies

1 other study available for ono 1078 and Atrophy

ArticleYear
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats.
    The Journal of pharmacy and pharmacology, 2011, Volume: 63, Issue:4

    Topics: Acetates; Administration, Oral; Animals; Antipyrine; Atrophy; Behavior, Animal; Brain Injury, Chroni

2011